Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Saskatchewan

$20,000.00

Mass spectrometric approaches to assess the biodistribution and fate of cationic surfactants used as drug delivery nanoparticles

FY 2016-17

Summary
In the pharmaceutical industry, the fastest growing area is drug delivery, accounting currently for more than $80 billion of total value, including gene delivery. The latter has gained momentum with the recent first approval in the European Union of the gene therapy, Glybera? for the treatment of genetic lipid disorders. In fact, there are 5000 genetic diseases that do not have a cure. Therefore, it is not surprising that over 2000 clinical trials (i.e. human testing) have been conducted, evaluating various gene therapy strategies. Among the various gene delivery systems, cationic-lipid nanoparticles have demonstrated a great potential as chemical vectors. However, it has been shown that different cationic lipids have varying toxicological profiles in cells as toxicity is dependent on the chemical structure. It is not fully understood what happens to the delivery system once the gene is transferred to the targeted tissue/cell. Such basic knowledge is lacking and is critical for understanding the relationship between structure and toxicity, leading to the development of efficient and safe lipid-based nanoparticles. My research program aims at addressing this essential gap in knowledge. I am evaluating the fate of two structurally related cationic lipid groups belonging to the subfamily gemini surfactants. These compounds can assemble to form nanoparticles when complexed with genetic materials. The main short-term goal of my research program is to determine the fate of gemini surfactant-based nanoparticles within cells, utilizing state-of-the-art mass spectrometric techniques. The proposed research will monitor the subcellular localization and degradation profile of gemini surfactants. Their behavior within cells may explain the variation in the toxic profiles among different compounds. We will develop methods to determine the cellular fate of gemini surfactants including cellular localization and metabolic byproduct formation. My research program will contribute to the basic understanding of such behavior. The knowledge produced will be used in engineering new gemini surfactants that are non-toxic and efficient in drug delivery. In the long term, my research program can impact the development of safe and efficient therapeutic products. It should be noted that gemini surfactants have many other industrial applications such as detergents, cosmetics and solubilization agents. The proposed work can allow for the assessment of the safety of gemini surfactants regardless of the application.
Program
Discovery Grants Program - Individual
Location
Saskatchewan, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2015-03715
Name nom
ElAneed, Anas
Department département
Pharmacy and Nutrition, College of - Pharmacy and Nutrition, College of
Organization id
16
Institution établissement
University of Saskatchewan
Province en
Saskatchewan
Province fr
Saskatchewan
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2015
Award amount
20000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Partie
2
Nb partie
5
Application title
Mass spectrometric approaches to assess the biodistribution and fate of cationic surfactants used as drug delivery nanoparticles
Keyword
NSERC
Application summary
In the pharmaceutical industry, the fastest growing area is drug delivery, accounting currently for more than $80 billion of total value, including gene delivery. The latter has gained momentum with the recent first approval in the European Union of the gene therapy, Glybera? for the treatment of genetic lipid disorders. In fact, there are 5000 genetic diseases that do not have a cure. Therefore, it is not surprising that over 2000 clinical trials (i.e. human testing) have been conducted, evaluating various gene therapy strategies. Among the various gene delivery systems, cationic-lipid nanoparticles have demonstrated a great potential as chemical vectors. However, it has been shown that different cationic lipids have varying toxicological profiles in cells as toxicity is dependent on the chemical structure. It is not fully understood what happens to the delivery system once the gene is transferred to the targeted tissue/cell. Such basic knowledge is lacking and is critical for understanding the relationship between structure and toxicity, leading to the development of efficient and safe lipid-based nanoparticles. My research program aims at addressing this essential gap in knowledge. I am evaluating the fate of two structurally related cationic lipid groups belonging to the subfamily gemini surfactants. These compounds can assemble to form nanoparticles when complexed with genetic materials. The main short-term goal of my research program is to determine the fate of gemini surfactant-based nanoparticles within cells, utilizing state-of-the-art mass spectrometric techniques. The proposed research will monitor the subcellular localization and degradation profile of gemini surfactants. Their behavior within cells may explain the variation in the toxic profiles among different compounds. We will develop methods to determine the cellular fate of gemini surfactants including cellular localization and metabolic byproduct formation. My research program will contribute to the basic understanding of such behavior. The knowledge produced will be used in engineering new gemini surfactants that are non-toxic and efficient in drug delivery. In the long term, my research program can impact the development of safe and efficient therapeutic products. It should be noted that gemini surfactants have many other industrial applications such as detergents, cosmetics and solubilization agents. The proposed work can allow for the assessment of the safety of gemini surfactants regardless of the application.